SavedAdd your journal

Journals / The Turkish Journal of Ear Nose and Throat / 2018 / Cilt: 28 - Sayı: 4

The importance of serum paraoxonase, arylesterase and ischemia modified albumin levels in evaluation of patients with Bell palsy

Esin ÇALCI
ÇİĞDEM YÜCEL
Turan TURHAN
Burak TÜRKAY
Aydın ACAR
Pages
168–172
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: Paraoxonase and ARE levels of the patient group were significantly lower than controls p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to evaluate the possible roles of paraoxonase PON , arylesterase ARE , ischemia-modified albumin IMA and albumin-adjusted IMA levels in patients with Bell palsy.
📊
Key Findings & Data:Patients and Methods: Thirty patients with Bell palsy and 30 healthy control subjects were included in the study.
💡
Conclusion & Impact:Results: Paraoxonase and ARE levels of the patient group were significantly lower than controls p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Arylesterase · Bell palsy · ischemia-modified albumin

Abstract

Objectives: This study aims to evaluate the possible roles of paraoxonase PON , arylesterase ARE , ischemia-modified albumin IMA and albumin-adjusted IMA levels in patients with Bell palsy. Patients and Methods: Thirty patients with Bell palsy and 30 healthy control subjects were included in the study. Serum PON, ARE, IMA, albumin-adjusted IMA and lipid profiles were measured. Results: Paraoxonase and ARE levels of the patient group were significantly lower than controls p

🔖

Cite This Article

ÇALCI, E., YÜCEL, Ç., TURHAN, T., TÜRKAY, B., ACAR, A. (2018). The importance of serum paraoxonase, arylesterase and ischemia modified albumin levels in evaluation of patients with Bell palsy. The Turkish Journal of Ear Nose and Throat, Cilt: 28 - Sayı: 4, 168–172. https://ajindex.com/articles/362610

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Lalwani AK. Current Diagnosis & Treatment in Otolaryngology-Head & Neck Surgery. New York: McGraw-Hill; 2008. p. 885-930. Gilden DH. Clinical practice. Bell’s Palsy. N Engl J Med 2004;351:1323-31.
  2. Kucur C, Baştürk A, Gürsel AO. Bell paralizisi: Tanı, tedavi ve klinik takibi. Bakırköy Tıp Dergisi 2011;7:56- 9. Yadav AS, Saini M. Evaluation of systemic antioxidant level and oxidative stress in relation to lifestyle and disease progression in asthmatic patients. J Med Biochem 2016;35:55-62.
  3. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:473-80.
  4. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991;286:152-4.
  5. Awadallah SM, Atoum MF, Nimer NA, Saleh SA. Ischemia modified albumin: an oxidative stress marker in b-thalassemia major. Clin Chim Acta 2012;41:907-10.
  6. Liyan C, Jie Z, Yonghua W, Xiaozhou H. Assay of ischemia-modified albumin and C-reactive protein for early diagnosis of acute coronary syndromes. J Clin Lab Anal 2008;22:45-9.
  7. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983;35:1126-38.
  8. Haagen L, Brock A. A new automated method for phenotyping arylesterase (EC 3.1.1.2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 1992;30:391-5.
  9. Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt- albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med 2000;19:311-5.
  10. Lippi G, Montagnana M, Salvagno GL, Guidi GC. Standardization of ischemia-modified albumin testing: adjustment for serum albumin. Clin Chem Lab Med 2007;45:261-2.
  11. Cokluk E, Sekeroglu MR, Aslan M, Balahoroglu R, Bilgili SG, Huyut Z. Determining oxidant and antioxidant status in patients with genital warts. Redox Rep 2015;20:210-4.
  12. Canales A, Sánchez-Muniz FJ. Paraoxonase, something more than an enzyme?. Med Clin (Barc) 2003;121:537- 48. [Abstract] Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995;96:2881-91.
  13. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free